Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194032 | 0.83 | CPN1 (0.47) | CPN1CPB2SMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL17724586 | 0.82 | KDM4E (0.51) | SMN1; SMN2MMP8LMNATDP1MEN1 | |
| SCHEMBL6163227 | 0.81 | SMN1; SMN2 (0.48) | CPN1CPB2SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL20839665 | 0.81 | CPN1 (0.46) | CPN1CPB2SMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL1366779 | 0.81 | CPN1 (0.53) | CPN1CPB2SMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL1104877 | 0.81 | CPN1 (0.53) | CPN1CPB2SMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL30573232 | 0.81 | CPN1 (0.53) | CPN1CPB2SMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL1366777 | 0.81 | CPN1 (0.53) | CPN1CPB2SMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL2312705 | 0.80 | MMP8 (0.54) | SMN1; SMN2L3MBTL1MMP8LMNAALDH1A1 | |
| SCHEMBL12951609 | 0.80 | MMP8 (0.54) | SMN1; SMN2L3MBTL1MMP8LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486491-B1 | CARBOXYLIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7351705-B2 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | UACA, CPA3, HCAR1 | CPN1 34/4885CPB2 251/4885SMN1; SMN2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.